Skip to main content
Physical/Tech

Giredestrant plus Everolimus in Advanced Breast Cancer.

| Source: The New England journal of medicine

Giredestrant and everolimus target the estrogen receptor (ER) pathway and the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway, respectively, which are implicated in endocrine-therapy resistance. In this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who had disease progression or recurrence after receipt of a

Giredestrant and everolimus target the estrogen receptor (ER) pathway and the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway, respectively, which are implicated in endocrine-therapy resistance. In this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who had disease progression or recurrence after receipt of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor plus endocrine therapy. Patients were assigned, in a 1:1 ratio, to receive giredestrant plus everolimus (each given orally) or standard endocrine therapy (i.e., exemestane, fulvestrant, or tamoxifen) plus everolimus. The primary end point was investigator-assessed progression-free survival, evaluated first among patients with ESR1 -mutated tumors and then in the overall trial population. Overall, 373 patients underwent randomization, with 183 assigned to the giredestrant-everolimus group and 190 to the standard therapy-everolimus group. Among 207 patients with ESR1 -mutated tumors, the median progression-free survival was 10.0 months with giredestrant-everolimus and 5.5 months with standard therapy-everolimus (hazard ratio for disease progression or death, 0.38; 95% confidence interval [CI], 0.27 to 0.54; P<0.001). In the overall population, the median progression-free survival was 8.8 months with giredestrant-everolimus and 5.5 months with standard therapy-everolimus (hazard ratio, 0.56; 95% CI, 0.44 to 0.71; P<0.001). Adverse events occurred in 98.9% of patients who received giredestrant-everolimus and in 96.8% of those who received standard therapy-everolimus. The most common adverse events were stomatitis (in 47.3% of giredestrant-everolimus recipients and 48.9% of standard therapy-everolimus recipients), diarrhea (in 26.9% and 22.6%, respectively), and anemia (in 23.6% and 21.0%). An all-oral giredestrant-everolimus regimen led to significantly longer progression-free survival than standard endocrine therapy-everolimus among patients with ER-positive, HER2-negative advanced breast cancer who had received a CDK4/6 inhibitor previously, mainly in patients with ESR1 -mutated tumors. The incidence of adverse events was similar in the two groups. (Funded by Genentech; evERA Breast Cancer ClinicalTrials.gov number, NCT05306340.).

Read the original source →

Related Topics

Related Stories

Physical/Tech

Intuitive knowledge of object acoustics enables perceptual separation of physical variables from impact sounds.

Upon hearing objects collide, humans can estimate physical attributes such as material and mass. Although the physics of sound generation is well established, the inverse problem that listeners solve-of inferring physical parameters from sound-remains poorly understood. Classical accounts posit the use of acoustic cues that correlate with physical variables but do not explain how humans might distinguish multiple concurrent physical causes. To study this problem, we measured impulse responses fr

Continue reading
Physical/Tech

Sub-ice thermal gradients strongly influence winter depth use of an iconic cold-water fish.

In a thermally stratified lake, freshwater fish select habitats that align with their thermal preferences. While most studies of dimictic lakes have focused on habitat selection during summer stratification, less attention has been given to winter when inverse thermal stratification occurs with water temperatures between 0 to 4 °C. Our results show that winter thermal stratifications vary considerably among lakes. Much of the variation in winter depth use by the cold-water predator, Lake Tr

Continue reading
Physical/Tech

Emergent long-tailed dynamics in spin ice.

In this study, we reveal long-tail dynamics spontaneously arising from a magnetic system. Specifically, we consider a classical spin system and demonstrate the emergence of a spin-ice physics when drive-induced heating is well suppressed. We show that at high driving frequencies, magnetic monopole excitations exhibit nonergodic stochastic dynamics characterized by power-law-distributed trapping times with long tails-a behavior that persists even in the absence of driving. At intermediate driving

Continue reading
Physical/Tech

People know who to ask for favors despite underestimating compliance.

Whether and how people approach social interactions hinges on how they expect others to respond. Extensive social psychology research suggests that people are inaccurate interpersonal perceivers, overestimating negative responses (e.g., discomfort) and underestimating positive responses (e.g., appreciation) across a variety of social situations. However, this conclusion is based almost exclusively on mean-level bias analyses that obscure the dyadic nature of interpersonal judgment and rely on a

Continue reading
Physical/Tech

Mapping the Slow Propagation of Disorder across a Photoreceptor's Tertiary Structure with Time-Resolved Crystallography.

Order-disorder transitions allow many proteins to shift between compact and flexible/unfolded states, thereby acting as structural switches that regulate catalysis, signaling, recognition, and allostery. We applied time-resolved serial oscillation crystallography to establish the structural kinetics of the light-triggered order-disorder transition of an animal-like cryptochrome as a six-second-long molecular movie with near-atomic all-residue spatial resolution and millisecond temporal resolutio

Continue reading